Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab

被引:25
作者
Chou, Shaun [1 ]
Hwang, Shelley Ji Eun [2 ,3 ]
Carlos, Giuliana [2 ,3 ]
Wakade, Deepal [2 ,3 ]
Fernandez-Penas, Pablo [2 ,3 ]
机构
[1] Westmead Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[2] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
关键词
PD-1; nivolumab; pembrolizumab; CTLA-4; ipilimumab; immunotherapy; lichenoid inflammation; lichen planus; adverse drug reaction; ADVANCED MELANOMA; METASTATIC MELANOMA; UNTREATED MELANOMA; PEMBROLIZUMAB; NIVOLUMAB; PATHWAY; COHORT; CANCER; SAFETY;
D O I
10.1097/DAD.0000000000000587
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen-4 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti-PD-1 agents and 9 biopsies from 7 patients on anti-PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous. Nevertheless, there was frequent involvement of the superficial follicular epithelium and acrosyringium, and also a propensity to blister that occurred in approximately 20% of the biopsies. Occasional patients had disease closely resembling lichen planus, although all of these biopsies had some atypical features for lichen planus such as parakeratosis. Dermal eosinophils were common particularly in those with mild inflammation. The lichenoid reaction was responsive to topical steroid or oral systemic treatment in general, and the anti-PD-1 agent had to be ceased in only one patient.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 15 条
[1]   A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab [J].
Carlos, Giuliana ;
Anforth, Rachael ;
Chou, Shaun ;
Clements, Arthur ;
Fernandez-Penas, Pablo .
MELANOMA RESEARCH, 2015, 25 (03) :265-268
[2]   Grover Disease: A Reappraisal of Histopathological Diagnostic Criteria in 120 Cases [J].
Fernandez-Figueras, Maria-Teresa ;
Puig, Luis ;
Cannata, Pablo ;
Cuatrecases, Miriam ;
Quer, Ariadna ;
Ferrandiz, Carlos ;
Ariza, Aurelio .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2010, 32 (06) :541-549
[3]   Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].
Hamid, Omid ;
Robert, Caroline ;
Daud, Adil ;
Hodi, F. Stephen ;
Hwu, Wen-Jen ;
Kefford, Richard ;
Wolchok, Jedd D. ;
Hersey, Peter ;
Joseph, Richard W. ;
Weber, Jeffrey S. ;
Dronca, Roxana ;
Gangadhar, Tara C. ;
Patnaik, Amita ;
Zarour, Hassane ;
Joshua, Anthony M. ;
Gergich, Kevin ;
Elassaiss-Schaap, Jeroen ;
Algazi, Alain ;
Mateus, Christine ;
Boasberg, Peter ;
Tumeh, Paul C. ;
Chmielowski, Bartosz ;
Ebbinghaus, Scot W. ;
Li, Xiaoyun Nicole ;
Kang, S. Peter ;
Ribas, Antoni .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144
[4]   Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer [J].
Harshman, Lauren C. ;
Choueiri, Toni K. ;
Drake, Charles ;
Hodi, F. Stephen, Jr. .
CANCER JOURNAL, 2014, 20 (04) :272-280
[5]   Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort [J].
Hwang, Shelley Ji Eun ;
Carlos, Giuliana ;
Wakade, Deepal ;
Byth, Karen ;
Kong, Benjamin Y. ;
Chou, Shaun ;
Carlino, Matteo S. ;
Kefford, Richard ;
Fernandez-Penas, Pablo .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) :455-+
[6]   Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy [J].
Joseph, Richard W. ;
Cappel, Mark ;
Goedjen, Brent ;
Gordon, Matthew ;
Kirsch, Brandon ;
Gilstrap, Cheryl ;
Bagaria, Sanjay ;
Jambusaria-Pahlajani, Anokhi .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) :18-22
[7]  
Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
[8]   Targeting the PD-1 pathway: a promising future for the treatment of melanoma [J].
Mamalis, Andrew ;
Garcha, Manveer ;
Jagdeo, Jared .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2014, 306 (06) :511-519
[9]   Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma [J].
Postow, Michael A. ;
Chesney, Jason ;
Pavlick, Anna C. ;
Robert, Caroline ;
Grossmann, Kenneth ;
McDermott, David ;
Linette, Gerald P. ;
Meyer, Nicolas ;
Giguere, Jeffrey K. ;
Agarwala, Sanjiv S. ;
Shaheen, Montaser ;
Ernstoff, Marc S. ;
Minor, David ;
Salama, April K. ;
Taylor, Matthew ;
Ott, Patrick A. ;
Rollin, Linda M. ;
Horak, Christine ;
Gagnier, Paul ;
Wolchok, Jedd D. ;
Hodi, F. Stephen .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2006-2017
[10]   Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].
Robert, Caroline ;
Schachter, Jacob ;
Long, Georgina V. ;
Arance, Ana ;
Grob, Jean Jacques ;
Mortier, Laurent ;
Daud, Adil ;
Carlino, Matteo S. ;
McNeil, Catriona ;
Lotem, Michal ;
Larkin, James ;
Lorigan, Paul ;
Neyns, Bart ;
Blank, Christian U. ;
Hamid, Omid ;
Mateus, Christine ;
Shapira-Frommer, Ronnie ;
Kosh, Michele ;
Zhou, Honghong ;
Ibrahim, Nageatte ;
Ebbinghaus, Scot ;
Ribas, Antoni .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532